September 16, 2022
CATEGORIES: Lupus Nephritis
First posted September 15, 2022, Updated September 15, 2022
This trial aims to learn about the safety and tolerability of daxdilimab (trial drug), and to learn about the effect it has on lupus nephritis when combined with standard treatment (that is, mycophenolate mofetil [MMF] or mycophenolic acid [MPA] and corticosteroids [also called steroids, which are a type of anti-inflammatory drugs]) when compared to combination of placebo and standard treatment.
To Learn More Contact
Call Horizon Therapeutics at 1-866-479-6742 or by email to firstname.lastname@example.org
ClinicalTrials.gov identifier (NCT number): NCT05540665